Two of the American studies were directed by Dr. Bernard Fisher of the University of Pittsburgh as part of the National Surgical and Adjuvant Breast and Bowel Project.

"We feel raloxifene is the winner of this trial," said Dr. D. Lawrence Wickerham, associate chairman of the National Surgical Adjuvant Breast and Bowel Project, which coordinated the experiment.

To validate the test, company scientists and academic collaborators from the National Surgical Adjuvant Breast and Bowel Project used samples from 668 women.

Dr. Fisher had been director of the National Surgical Adjuvant Breast and Bowel Project since 1967.

These were the four published studies and their key results: * The National Surgical Adjuvant Breast and Bowel Project treated 679 women with tumors that did not respond to hormones.

Fisher ER, Redmond C, Fisher B, et al.: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP).

Wickerham is STAR trial's protocol officer and the associate chair of the National Surgical Adjuvent Breast and Bowel Project (NSABP).

Fisher ER, Land SR, Fisher B, et al.: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ.

The National Surgical Adjuvant Breast and Bowel Project, which has its headquarters at the University of Pittsburgh, did not respond to telephone calls.

Dr. Paik, who is with the National Surgical Adjuvant Breast and Bowel Project, said that about 40 percent of women had intermediate levels of Her2.